Corteva, Inc. (NYSE:CTVA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Corteva, Inc. (NYSE:CTVA) have been assigned an average recommendation of “Moderate Buy” from the twenty-three research firms that are currently covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $88.9048.

A number of research firms have recently issued reports on CTVA. Weiss Ratings upgraded Corteva from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, May 7th. Mizuho upped their price target on Corteva from $94.00 to $96.00 and gave the company an “outperform” rating in a research report on Thursday. The Goldman Sachs Group lifted their target price on Corteva from $88.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. BNP Paribas Exane upped their target price on Corteva from $74.00 to $77.00 in a report on Wednesday, May 6th. Finally, Wells Fargo & Company increased their price target on shares of Corteva from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 21st.

Corteva Price Performance

NYSE CTVA opened at $85.63 on Monday. Corteva has a 1 year low of $60.53 and a 1 year high of $85.95. The stock’s 50-day moving average price is $79.80 and its two-hundred day moving average price is $76.94. The company has a market cap of $57.27 billion, a PE ratio of 50.37, a PEG ratio of 2.62 and a beta of 0.56. The company has a current ratio of 1.47, a quick ratio of 1.03 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The business had revenue of $4.91 billion for the quarter, compared to analyst estimates of $4.64 billion. During the same quarter in the previous year, the business earned $1.13 earnings per share. The firm’s revenue was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts predict that Corteva will post 3.72 EPS for the current year.

Corteva Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Monday, June 1st were paid a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.8%. The ex-dividend date was Monday, June 1st. Corteva’s dividend payout ratio is currently 42.35%.

Hedge Funds Weigh In On Corteva

Hedge funds have recently modified their holdings of the stock. JPL Wealth Management LLC purchased a new stake in shares of Corteva during the third quarter worth $25,000. Westfuller Advisors LLC grew its stake in Corteva by 2,764.3% in the first quarter. Westfuller Advisors LLC now owns 401 shares of the company’s stock valued at $34,000 after purchasing an additional 387 shares in the last quarter. Garton & Associates Financial Advisors LLC acquired a new position in Corteva in the 4th quarter worth about $27,000. Bank of Jackson Hole Trust purchased a new stake in shares of Corteva during the 4th quarter worth about $28,000. Finally, Cornerstone Financial Management LLC acquired a new stake in shares of Corteva during the 4th quarter valued at about $29,000. 81.54% of the stock is owned by institutional investors and hedge funds.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.